Coherus Oncology (CHRS) Non-Current Assets (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Non-Current Assets data on file, last reported at $60.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 1.48% year-over-year to $60.0 million; the trailing twelve-month figure through Mar 2026 stood at $226.4 million (down 46.18% YoY), and the FY2025 full-year result was $51.6 million, down 51.72% from the prior year.
• Non-Current Assets improved to $60.0 million in Q1 2026, from $51.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $154.0 million in Q4 2023 to a low of $51.6 million in Q4 2025.
• A 5-year average of $95.9 million and a median of $99.2 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 57.3% in 2024 and tumbled 59.14% in 2025, its largest moves.
• Tracing CHRS's Non-Current Assets over 5 years: stood at $99.6 million in 2022, then soared by 54.57% to $154.0 million in 2023, then tumbled by 30.54% to $107.0 million in 2024, then tumbled by 51.72% to $51.6 million in 2025, then climbed by 16.17% to $60.0 million in 2026.
• Business Quant data shows CHRS's Non-Current Assets at $60.0 million in Q1 2026, $51.6 million in Q4 2025, and $55.6 million in Q3 2025.